Biota seeking A$308-A$430 million in Relenza losses

Biota (ASX:BTA) said it is seeking A$308-A$430 million ($235-$328 million) in damages in a lawsuit against GlaxoSmithKline (LSE:GSK; GSK) for failing to support and promote BTA's inhaled influenza drug Relenza zanamavir. The loss estimates assume that Relenza would have achieved a 40% market share and that GSK had introduced an improved inhaler and sought an expanded label for prevention of flu. ...